Bai Ge, Wang Lei, Zhang Li, Eli Mayinur
Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Ürümqi, China.
J Cell Mol Med. 2025 Jul;29(14):e70724. doi: 10.1111/jcmm.70724.
While prior research linked ZNF468 to radioresistance in oesophageal squamous cell carcinoma (ESCC), its broader role in ESCC progression remained unclear. This study elucidates these functions and underlying mechanisms. Immunohistochemistry on clinical ESCC tissues demonstrated ZNF468 upregulation, which correlated with unfavourable patient outcomes and increased Aurora A expression. In vitro experiments, including assessments of proliferation, apoptosis, migration and invasion, revealed that ZNF468 overexpression enhanced these oncogenic phenotypes in ESCC cells, while its knockdown produced inhibitory effects. These findings were corroborated in vivo using subcutaneous tumour and lung metastasis models. Mechanistically, ZNF468 was found to upregulate AURKA expression, subsequently activating the PI3K/AKT signalling pathway, thereby promoting cell proliferation and epithelial-mesenchymal transition (EMT). Importantly, pharmacological inhibition of AURKA or the PI3K/AKT pathway significantly attenuated the pro-tumorigenic effects driven by ZNF468. Furthermore, AKT was shown to augment ZNF468 protein stability and transcriptional activity, establishing a ZNF468/AURKA/PI3K/AKT positive feedback loop. In conclusion, this study identifies a critical positive feedback mechanism involving ZNF468/AURKA/PI3K/AKT that significantly promotes ESCC progression, underscoring ZNF468 as a potential therapeutic target.
虽然先前的研究将ZNF468与食管鳞状细胞癌(ESCC)的放射抗性联系起来,但其在ESCC进展中的更广泛作用仍不清楚。本研究阐明了这些功能及其潜在机制。对临床ESCC组织进行免疫组织化学分析显示ZNF468上调,这与患者预后不良和极光激酶A(Aurora A)表达增加相关。体外实验,包括对增殖、凋亡、迁移和侵袭的评估,显示ZNF468过表达增强了ESCC细胞中的这些致癌表型,而敲低ZNF468则产生抑制作用。使用皮下肿瘤和肺转移模型在体内证实了这些发现。从机制上讲,发现ZNF468上调AURKA表达,随后激活PI3K/AKT信号通路,从而促进细胞增殖和上皮-间质转化(EMT)。重要的是,对AURKA或PI3K/AKT通路的药理学抑制显著减弱了ZNF468驱动的促肿瘤作用。此外,AKT被证明可增强ZNF468蛋白稳定性和转录活性,从而建立了一个ZNF468/AURKA/PI3K/AKT正反馈环。总之,本研究确定了一种涉及ZNF468/AURKA/PI3K/AKT的关键正反馈机制,该机制显著促进ESCC进展,强调ZNF468作为一个潜在的治疗靶点。